First Patients Treated in New jCell Clinical Trial for Retinitis Pigmentosa

At A Race Against Blindness, we closely follow scientific advances that bring new hope to families affected by inherited retinal diseases like Bardet-Biedl Syndrome (BBS) and retinitis pigmentosa (RP). One of the most promising efforts comes from jCyte, Inc. , which recently announced that the first patients have been treated in its JC02-88 clinical trial of jCell (famzeretcel) — a potential regenerative therapy for RP. Why This Trial Matters Retinitis pigmentosa is a rare genetic condition that causes gradual loss of the rod and cone cells in the retina, leading to progressive vision loss. Symptoms often begin in adolescence, with many individuals becoming legally blind by midlife. More than 2 million people worldwide — including about 100,000 in the U.S. — are affected. Currently, there are no approved treatments for most RP patients. That’s why this new trial marks such an important milestone. What Is jCell? jCell is an innovative allogeneic cell therapy designed to protect and possibly restore vision in people with RP. Unlike many gene therapies that are tailored to specific muta